The Central Drugs Standard Control Organisation (CDSCO) gave its nod to the vaccine for use as both primary series as well as a heterologou...

Covaxin - and has submitted the data to the Drugs Controller General of India (DCGI) for the review. Hyderabad based Bharat Biotech has sou...

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candid...

According to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...

According to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...

The date of the meeting is yet to be fixed. India's drug controller had in January this year given permission to Bharat Biotech to conduct ...

Nasal vaccines are administered, as the name suggests, through the nose.

"Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce/stop transmission," the company said in a stat...

The trials of the Intranasal vaccine will take place at nine different sites of the country.

The company had also sought approval from the SEC to use its intranasal vaccine as a booster dose, to which the SEC asked the company to su...

An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transm...

"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 part...

BBV154 is the first intranasal Covid-19 vaccine to undergo human trials in India. It has now received approval to conduct Phase 2 randomise...

Early stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years, and the doses were found to be wel...

"Based on the safety and immunogenicity data of the phase 1 clinical trial, the company would be given permission for conducting phase 2 cl...

Vaccine producer Bharat Biotech International (BBIL) could begin phase I/II human clinical trials for its single-dose intranasal vaccine ca...

In a statement on Wednesday, the biotechnology company said it owns the rights to distribute the vaccine in all markets except the US, Japa...